Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

FoxP3+ Regulatory T Cells in Peripheral Blood of Patients with Epithelial Ovarian Cancer

Background: Ovarian cancer is the fifth leading cause of death from malignancy in women. CD4 +CD25+FoxP3+ regulatory T (Treg) cells are a subset of T lymphocytes with great inhibitory impact on immune response. Objectives: To investigate the percentage of CD4 +CD25+FoxP3+ regulatory T cells in the peripheral blood of the Iranian patients with epithelial ovarian cancer compared to healthy women ...

متن کامل

foxp3+ regulatory t cells in peripheral blood of patients with epithelial ovarian cancer

background: ovarian cancer is the fifth leading cause of death from malignancy in women. cd4 +cd25+foxp3+ regulatory t (treg) cells are a subset of t lymphocytes with great inhibitory impact on immune response. objectives: to investigate the percentage of cd4 +cd25+foxp3+ regulatory t cells in the peripheral blood of the iranian patients with epithelial ovarian cancer compared to healthy women ...

متن کامل

Increased Expression of TRAIL and Its Receptors on Peripheral T-Cells in Type 1 Diabetic Patients

Background: Type-I diabetes is an autoimmune inflammatory disease in which pancreatic ß-cells are selectively destroyed by infiltrating cells. TNF-related apoptosis-inducing ligand (TRAIL) is a type-II membrane protein of the TNF superfamily which is expressed in different tissues, including pancreas and lymphocytes. In humans, TRAIL interacts with four membrane receptors. TRAIL-R1 and TRAIL-R2...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Clinical and Experimental Dermatology

سال: 2009

ISSN: 0307-6938,1365-2230

DOI: 10.1111/j.1365-2230.2008.03001.x